April 8, 2009 -Coartem (artemether 20 mg/lumefantrine 120 mg), the leading artemisinin-based combination treatment (ACT) for malaria worldwide, has been approved by the US FDA.
Coartem is a fixed-dose combination of two novel antimalarials. It is a highly-effective three-day malaria treatment with cure rates of over 96% even in areas of multi-drug resistance.
The details can be read here.
No comments:
Post a Comment